Where do Royalty Pharma's ratios come from?

Every ratio is computed from Royalty Pharma's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.

Royalty Pharma RPRX Ratios & Valuation

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Profitability
Operating margin	294.6%+84.5pp	210.1%—	——	——
Net margin	157.7%+3.4pp	154.3%—	——	——
Returns
Return on equity	37.2%+2.2pp	34.9%—	——	——
Return on assets	20.3%-0.1pp	20.4%—	——	——
Return on invested capital	41.2%+11.0pp	30.2%—	——	——
Efficiency
Asset turnover	0.5×0.0×	0.5×0.0×	0.6×0.0×	0.5×—
Liquidity
Current ratio	8.7×-16.1×	24.8×-1.4×	26.3×-19.1×	45.4×-1.2×
Quick ratio	8.7×-16.1×	24.8×-1.4×	26.3×-19.1×	45.4×-1.2×
Cash ratio	4.2×-10.5×	14.7×+0.8×	13.9×-13.2×	27.1×+4.2×
Leverage
Debt-to-equity	3.5×+0.6×	2.9×+0.2×	2.7×-0.1×	2.8×+0.3×
Debt-to-assets	1.8×+0.1×	1.7×+0.1×	1.6×0.0×	1.6×+0.1×
Interest coverage	25.2×+1.8×	23.4×—	——	——
Per Share
Book value per share	$68.22+1.0%	$67.56+3.9%	$65.04-10.6%	$72.75-3.2%
Valuation
Market capitalization	$60.48B+22.2%	$49.5B-9.1%	$54.48B-22.5%	$70.3B+1.9%
Enterprise value	$90.78B+22.7%	$73.97B-1.9%	$75.43B-18.1%	$92.13B+2.8%
Price / earnings	68.5×+9.6×	59×—	——	——
Price / sales	26×+4.0×	22×-1.2×	23.2×-8.0×	31.2×+0.5×
Price / book	6.3×+1.3×	4.9×-0.6×	5.5×-1.4×	7×+0.2×
EV / sales	39×+6.2×	32.9×+0.8×	32.1×-8.8×	40.9×+1.0×
Earnings yield	24.5%-3.6pp	28.1%—	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Royalty Pharma.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

Where do Royalty Pharma's ratios come from?: Every ratio is computed from Royalty Pharma's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.